A head-To-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder

International Journal of Neuropsychopharmacology

Volumn 16, Issue 9, 2013, Pages 1959-1973

  Ni, Hsing Chang ^a,b,c   Shang, Chi Yung ^a,b   Gau, Susan Shur Fen ^a,b,d   Lin, Yu Ju ^a,e   Huang, Hui Chun ^f   Yang, Li Kuang ^a,g  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d Graduate Institute of Brain and Mind Sciences   (Taiwan)

^e FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Adult ADHD; atomoxetine; executive function; methylphenidate.

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE;

ADULT; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; CAMBRIDGE NEUROPSYCHOLOGICAL TEST AUTOMATED BATTERY; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; EXECUTIVE FUNCTION; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PATIENT COMPLIANCE; PLANNING; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; SHORT TERM MEMORY; SPATIAL ORIENTATION; STOCKINGS OF CAMBRIDGE; SYMPTOM ASSESSMENT; VISUAL INFORMATION; WORKING MEMORY;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHI-SQUARE DISTRIBUTION; DOPAMINE UPTAKE INHIBITORS; EXECUTIVE FUNCTION; FEMALE; HUMANS; LINEAR MODELS; MALE; MEMORY, SHORT-TERM; METHYLPHENIDATE; NEUROPSYCHOLOGICAL TESTS; PROPYLAMINES; TAIWAN; TIME FACTORS; TREATMENT OUTCOME; VISUAL PERCEPTION;

EID: 84883412659     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000357     Document Type: Article

References (93)

1. Adler LA, Zimmerman B, Starr HL, Silber S, Palumbo J, Orman C, Spencer T (2009a) Efficacy and safety of OROS methylphenidate in adults with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 29:239-247
2. Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D (2009b) Once-daily atomoxetine for adult attention-deficit/ hyperactivity disorder: a 6-month, double-blind trial. J Clin Psychopharmacol 29:44-50
3. Advokat C (2010) What are the cognitive effects of stimulant medications? Emphasis on adults with attention-deficit/ hyperactivity disorder (ADHD). Neurosci Biobehav Rev 34:1256-1266
4. Arnsten AF (2006a) Fundamentals of attention-deficit/ hyperactivity disorder: circuits and pathways. J Clin Psychiatry 67(Suppl. 8):7-12
5. Arnsten AF (2006b) Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 31:2376-2383
6. Arnsten AF (2009) Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 23(Suppl. 1):33-41
7. Arnsten AF (2011) Catecholamine influences on dorsolateral prefrontal cortical networks. Biol Psychiatry 69:e89-e99
8. Arnsten AF, Li BM (2005) Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 57:1377-1384
9. Arnsten AF, Pliszka SR (2011) Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav 99:211-216
10. Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003) Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 54:1465-1468
11. Barnett R, Maruff P, Vance A, Luk ES, Costin J, Wood C, Pantelis C (2001) Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory. Psychol Med 31:1107-1115
12. Bedard AC, Martinussen R, Ickowicz A, Tannock R (2004) Methylphenidate improves visual-spatial memory in children with attention-deficit/hyperactivity disorder. Am Acad Child Adolesc Psychiatry 43:260-268
13. Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC (2006) Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 60:1111-1120
14. Biederman J, Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366:237-248
15. Biederman J, Petty CR, Fried R, Doyle AE, Spencer T, Seidman LJ, Gross L, Poetzl K, Faraone SV (2007) Stability of executive function deficits into young adult years: a prospective longitudinal follow-up study of grown up males with ADHD. Acta Psychiatr Scand 116:129-136
16. Biederman J, Petty CR, Doyle AE, Spencer T, Henderson CS, Marion B, Fried R, Faraone SV (2008a) Stability of executive function deficits in girls with ADHD: a prospective longitudinal follow-up study into adolescence. Dev Neuropsychol 33:44-61
17. Biederman J, Seidman LJ, Petty CR, Fried R, Doyle AE, Cohen DR, Kenealy DC, Faraone SV (2008b) Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 69:1150-1156
18. Boonstra AM, Kooij JJ, Oosterlaan J, Sergeant JA, Buitelaar JK (2005) Does methylphenidate improve inhibition and other cognitive abilities in adults with childhood-onset ADHD? J Clin Exp Neuropsychol 27:278-298
19. Bouffard R, Hechtman L, Minde K, Iaboni-Kassab F (2003) The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Can J Psychiatry 48:546-554
20. Brown TE, Holdnack J, Saylor K, Adler L, Spencer T, Williams DW, Padival AK, Schuh K, Trzepacz PT, Kelsey D (2011) Effect of atomoxetine on executive function impairments in adults with ADHD. JAtten Disord 15:130-138
21. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology 27:699-711
22. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ (2006) Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 311:861-863
23. Chamberlain SR, Del Campo N, Dowson J, Muller U, Clark L, Robbins TW, Sahakian BJ (2007) Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 62:977-984
24. Chamberlain SR, Robbins TW, Winder-Rhodes S, Muller U, Sahakian BJ, Blackwell AD, Barnett JH (2011) Translational approaches to frontostriatal dysfunction in attention-deficit/ hyperactivity disorder using a computerized neuropsychological battery. Biol Psychiatry 69:1192-1203
25. Chang LR, Gau SS, Chiu YN, Wu YY (2012) Father's parenting and father-child relationship among children and adolescents with attention-deficit/hyperactivity disorder. Compr Psychiatry 54:128-140
26. Clatworthy PL, Lewis SJ, Brichard L, Hong YT, Izquierdo D, Clark L, Cools R, Aigbirhio FI, Baron JC, Fryer TD, Robbins TW (2009) Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J Neuroscience 29:4690-4696
27. Coghill D (2010) The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs 24:843-866
28. Collette F, Van der Linden M (2002) Brain imaging of the central executive component of working memory. Neurosci Biobehav Rev 26:105-125
29. Coull JT, Jones ME, Egan TD, Frith CD, Maze M (2004) Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage 22:315-322
30. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW (2011) The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/ hyperactivity disorder. Biol Psychiatry 69:e145-e157
31. De Martino B, Strange BA, Dolan RJ (2008) Noradrenergic neuromodulation of human attention for emotional and neutral stimuli. Psychopharmacology 197:127-136
32. Diamantopoulou S, Rydell AM, Thorell LB, Bohlin G (2007) Impact of executive functioning and symptoms of attention deficit hyperactivity disorder on children's peer relations and school performance. Dev Neuropsychol 32:521-542
33. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW (1989) Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 27:1329-1343
34. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology 131:196-206
35. Faraone SV, Glatt SJ (2010) A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-Analysis of effect sizes. J Clin Psychiatry 71:754-763
36. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J (2004) Meta-Analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 24:24-29
37. Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, Seidman L (2005) Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 15:664-670
38. Gau SS, Chiang HL (2009) Sleep problems and disorders among adolescents with persistent and subthreshold attention-deficit/hyperactivity disorders. Sleep 32:671-679
39. Gau SS, Shang CY (2010a) Executive functions as endophenotypes in ADHD: evidence from the Cambridge Neuropsychological Test Battery (CANTAB). J Child Psychol Psychiatry 51:838-849
40. Gau SS, Shang CY (2010b) Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine. Int J Neuropsychopharmacol 13:243-256
41. Gau SS, Chong MY, Chen TH, Cheng AT (2005) A 3-year panel study of mental disorders among adolescents in Taiwan. Am J Psychiatry 162:1344-1350
42. Gau SS, Shen HY, Soong WT, Gau CS (2006) An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 16:441-455
43. Gau SS, Chong MY, Yang P, Yen CF, Liang KY, Cheng AT (2007) Psychiatric and psychosocial predictors of substance use disorders among adolescents: longitudinal study. Br J Psychiatry 190:42-48
44. Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS (2008) National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. J Clin Psychiatry 69:131-140
45. Gau SS, Chiu CD, Shang CY, Cheng AT, Soong WT (2009) Executive function in adolescence among children with attention-deficit/hyperactivity disorder in Taiwan. J Dev Behav Pediatr 30:525-534
46. Gau SS, Ni HC, Shang CY, Soong WT, Wu YY, Lin LY, Chiu YN (2010) Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder. Aust N Z J Psychiatry 44:135-143
47. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41:26S-49S
48. Gualtieri CT, Ondrusek MG, Finley C (1985) Attention deficit disorders in adults. Clin Neuropharmacol 8:343-356
49. Gualtieri CT, Wargin W, Kanoy R, Patrick K, Shen CD, Youngblood W, Mueller RA, Breese GR (1982) Clinical studies of methylphenidate serum levels in children and adults. J Am Acad Child Adolesc Psychiatry 21:19-26
50. Hechtman L, Abikoff H, Klein RG, Weiss G, Respitz C, Kouri J, Blum C, Greenfield B, Etcovitch J, Fleiss K, Pollack S (2004) Academic achievement and emotional status of children with ADHD treated with long-Term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43:812-819
51. Hinshaw SP, Carte ET, Fan C, Jassy JS, Owens EB (2007) Neuropsychological functioning of girls with attentiondeficit/ hyperactivity disorder followed prospectively into adolescence: evidence for continuing deficits? Neuropsychology 21:263-273
52. Kempton S, Vance A, Maruff P, Luk E, Costin J, Pantelis C (1999) Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children. Psychol Med 29:527-538
53. Kessler RC, Adler L, Ames M, Demler O, Faraone S, Hiripi E, Howes MJ, Jin R, Secnik K, Spencer T, Ustun TB,Walters EE (2005) The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 35:245-256
54. Kurscheidt JC, Peiler P, Behnken A, Abel S, Pedersen A, Suslow T, Deckert J (2008) Acute effects of methylphenidate on neuropsychological parameters in adults with ADHD: possible relevance for therapy. J Neural Transm 115:357-362
55. Levy F (2009) Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry 43:101-108
56. Luciana M (2003) Practitioner review: computerized assessment of neuropsychological function in children: clinical and research applications of the Cambridge Neuropsychological Testing Automated Battery (CANTAB). J Child Psychol Psychiatry 44:649-663
57. Luciana M, Nelson CA (1998) The functional emergence of prefrontally-guided working memory systems in four- to eight-year-old children. Neuropsychologia 36:273-293
58. Marquand AF, De Simoni S, O'Daly OG, Williams SC, Mourao-Miranda J, Mehta MA (2011) Pattern classification of working memory networks reveals differential effects of methylphenidate, atomoxetine, and placebo in healthy volunteers. Neuropsychopharmacology 36:1237-1247
59. Mattes JA, Boswell L, Oliver H (1984) Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 41:1059-1063
60. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW (2000) Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neuroscience 20:RC65
61. Mehta MA, Goodyer IM, Sahakian BJ (2004) Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry 45:293-305
62. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901
63. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112-120
64. Middleton FA, Strick PL (2001) Cerebellar projections to the prefrontal cortex of the primate. J Neuroscience 21:700-712
65. Middleton FA, Strick PL (2002) Basal-ganglia 'projections' to the prefrontal cortex of the primate. Cereb Cortex 12:926-935
66. Milner B (1971) Interhemispheric differences in the localization of psychological processes in man. Br Med Bull 27:272-277
67. Muller BW, Gimbel K, Keller-Pliessnig A, Sartory G, Gastpar M, Davids E (2007) Neuropsychological assessment of adult patients with attention-deficit/ hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 257:112-119
68. Nandam LS, Hester R, Wagner J, Cummins TD, Garner K, Dean AJ, Kim BN, Nathan PJ, Mattingley JB, Bellgrove MA (2011) Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. Biol Psychiatry 69:902-904
69. Newman LA, Darling J, McGaughy J (2008) Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology 200:39-50
70. Ni HC, Lin YJ, Gau SS, Huang HC, Yang LK (2013) An openlabel, randomized trial of methylphenidate and atomoxetine treatment in adults with ADHD. J Att Dis doi:10.1177/ 1087054713476549
71. Olton DS (1987) The radial arm maze as a tool in behavioral pharmacology. Physiol Behav 40:793-797
72. Pennington BF, Ozonoff S (1996) Executive functions and developmental psychopathology. J Child Psychol Psychiatry 37:51-87
73. Petrides M, Milner B (1982) Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia 20:249-262
74. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942-948
75. Rhodes SM, Coghill DR, Matthews K (2006) Acute neuropsychological effects of methylphenidate in stimulant drug-naive boys with ADHD II-broader executive and non-executive domains J Child Psychol Psychiatry 47:1184-1194
76. Robbins TW, Arnsten AF (2009) The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 32:267-287
77. Rossetti ZL, Carboni S (2005) Noradrenaline and dopamine elevations in the rat prefrontal cortex in spatial working memory. J Neuroscience 25:2322-2329
78. Sahakian B, Jones G, Levy R, Gray J, Warburton D (1989) The effects of nicotine on attention, information processing, and short-Term memory in patients with dementia of the Alzheimer type. Br J Psychiatry 154:797-800
79. Sahgal A (1987) Some limitations of indices derived from signal detection theory: evaluation of an alternative index for measuring bias in memory tasks. Psychopharmacology 91:517-520
80. Schulz KP, Fan J, Bedard AC, Clerkin SM, Ivanov I, Tang CY, Halperin JM, Newcorn JH (2012) Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 69:952-961
81. Seidman LJ (2006) Neuropsychological functioning in people with ADHD across the lifespan. Clin Psychol Rev 26:466-485
82. Shallice T (1982) Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 298:199-209
83. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 155:693-695
84. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ (2005) Neurocognitive effects of methylphenidate in adult attention-deficit/ hyperactivity disorder. Psychopharmacology 178:286-295
85. Vaidya CJ, Bunge SA, Dudukovic NM, Zalecki CA, Elliott GR, Gabrieli JD (2005) Altered neural substrates of cognitive control in childhood ADHD: evidence from functional magnetic resonance imaging. Am J Psychiatry 162:1605-1613
86. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF (2007) Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 10:376-384
87. Wender PH, Reimherr FW, Wood D, Ward M (1985) A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 142:547-552
88. Wesnes K, Warburton DM (1984) Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology 82:147-150
89. Wilens TE et al. (2006) Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 160:82-90
90. Willcutt EG, Doyle AE, Nigg JT, Faraone SV, Pennington BF (2005) Validity of the executive function theory of attention-deficit/hyperactivity disorder: a meta-Analytic review. Biol Psychiatry 57:1336-1346
91. Wilson HK, Cox DJ, Merkel RL, Moore M, Coghill D (2006) Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder. Arch Clin Neuropsychol 21:797-807.
92. Yang L, Cao Q, Shuai L, Li H, Chan RC, Wang Y (2011) Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. Int J Neuropsychopharmacol doi:10.1017/ S1461145711001490
93. Yeh CB, Gau SS, Kessler RC, Wu YY (2008) Psychometric properties of the Chinese version of the adult ADHD Self-report Scale. Int J Methods Psychiatr Res 17:45-54.